Leonard Green & Partners’s BriaCell Therapeutics BCTX Stock Holding History
Bought
Maintained
Sold
Other funds holding BCTX
SM
BCM
Leonard Green & Partners's BCTX Position: Q2 2022 in Review
Leonard Green & Partners sold out of BriaCell Therapeutics (BCTX) in Q2 2022, closing a stake of 3,333 shares — an estimated $5.07M sold.
Leonard Green & Partners first reported a position in BCTX in Q1 2022 and held it in 1 quarter. The position peaked at $5.07M in Q1 2022. 20 funds tracked by Wall St. Rank hold BCTX as of Q2 2022.
- Leonard Green & Partners reported no remaining BriaCell Therapeutics position as of Q2 2022 after selling out during the quarter.
- Leonard Green & Partners sold 3,333 BriaCell Therapeutics shares in Q2 2022, an estimated $5.07M.
- Leonard Green & Partners first reported a position in BriaCell Therapeutics in Q1 2022 and held it in 1 quarter.
- Leonard Green & Partners's BriaCell Therapeutics position peaked at $5.07M in Q1 2022.
- 20 funds tracked by Wall St. Rank held BriaCell Therapeutics as of Q2 2022.
Based on Leonard Green & Partners's 13F filing for Q2 2022, filed 15 Aug 2022.